Last Updated: November 16, 2026

QTERN Drug Patent Profile

« Back to Dashboard


Which patents cover Qtern, and what generic alternatives are available?

Qtern is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are seven patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in QTERN is dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride. There are two drug master file entries for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Qtern

Qtern was eligible for patent challenges on January 8, 2018.

There have been thirty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for QTERN?
  • What are the global sales for QTERN?
  • What is Average Wholesale Price for QTERN?
Paragraph IV (Patent) Challenges for QTERN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QTERN Tablets dapagliflozin; saxagliptin hydrochloride 5 mg/5 mg 209091 1 2020-07-29
QTERN Tablets dapagliflozin; saxagliptin hydrochloride 10 mg/5 mg 209091 5 2018-01-08

US Patents and Regulatory Information for QTERN

QTERN is protected by six US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-004 May 2, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-004 May 2, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-004 May 2, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Astrazeneca Ab QTERN dapagliflozin; saxagliptin hydrochloride TABLET;ORAL 209091-002 May 2, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-002 May 2, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QTERN

International Patents for QTERN

When does loss-of-exclusivity occur for QTERN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Patent: 53344
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 07001915
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 69374
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 57918
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 19059779
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 7155
Estimated Expiration: ⤷  Start Trial

Patent: 08015377
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 638
Patent: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 69374
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1406743
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Start Trial

Patent: 1546054
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Start Trial

Patent: 21245
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QTERN around the world.

Country Patent Number Title Estimated Expiration
Argentina 026024 COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS ⤷  Start Trial
Argentina 040032 C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO ⤷  Start Trial
Austria 295848 ⤷  Start Trial
Austria 353334 ⤷  Start Trial
Australia 2003237886 C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for QTERN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1506211 C300585 Netherlands ⤷  Start Trial PRODUCT NAME: DAPAGLIFLOZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211 PA2013008 Lithuania ⤷  Start Trial PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211 122013000033 Germany ⤷  Start Trial PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211 C20130006 00074 Estonia ⤷  Start Trial PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
1506211 92182 Luxembourg ⤷  Start Trial PRODUCT NAME: DAPAGLIFLOZINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

QTERN Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: October 25, 2026

Qtern is AstraZeneca’s fixed-dose combination of dapagliflozin and saxagliptin for adults with type 2 diabetes. Its commercial position has weakened as the market shifted toward dapagliflozin monotherapy, GLP-1 therapies, and newer combination regimens. Qtern remains commercially differentiated by combining an SGLT2 inhibitor with a DPP-4 inhibitor, but it lacks the growth profile and cardiovascular market access of Farxiga. AstraZeneca does not separately disclose material global Qtern revenue in its recent annual reporting, which limits product-level financial modeling.[1]

What is Qtern and how does it compete in type 2 diabetes?

Qtern combines two oral antihyperglycemic agents:

Product Active ingredients Drug classes Manufacturer FDA approval
Qtern Dapagliflozin 10 mg/saxagliptin 5 mg SGLT2 inhibitor/DPP-4 inhibitor AstraZeneca 2017
Farxiga Dapagliflozin SGLT2 inhibitor AstraZeneca 2014
Onglyza Saxagliptin DPP-4 inhibitor AstraZeneca 2009
Glyxambi Empagliflozin/linagliptin SGLT2 inhibitor/DPP-4 inhibitor Boehringer Ingelheim/Eli Lilly 2015
Trijardy XR Empagliflozin/linagliptin/metformin SGLT2 inhibitor/DPP-4 inhibitor/metformin Boehringer Ingelheim/Eli Lilly 2020

Qtern is administered once daily and is intended for patients who require additional glycemic control despite treatment with dapagliflozin or saxagliptin, or who are transitioning from the two individual products. The product does not contain metformin, which narrows its addressable population because metformin remains a common foundation therapy.[2]

The commercial rationale was to increase adherence and defend the combined use of two AstraZeneca diabetes products. That strategy was weakened by the rapid expansion of Farxiga’s indications in heart failure and chronic kidney disease. Those indications increased the value of dapagliflozin as a single-agent franchise while reducing the need to use Qtern as a primary growth vehicle.

What FDA regulatory status does Qtern have?

Qtern was approved by the FDA on September 27, 2017, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2] It was not approved for type 1 diabetes, diabetic ketoacidosis, weight reduction, heart failure, or chronic kidney disease.

FDA label and safety profile

The Qtern label carries warnings associated with both components:

  • Ketoacidosis and volume depletion risks from dapagliflozin.
  • Genitourinary infections and rare serious infections associated with SGLT2 inhibition.
  • Pancreatitis and heart-failure concerns associated with saxagliptin.
  • Hypoglycemia risk when used with insulin or insulin secretagogues.
  • Renal function limitations and dose considerations.

Qtern’s clinical value is therefore narrower than Farxiga’s. Farxiga has FDA indications for reducing the risk of hospitalization for heart failure in adults with heart failure and for reducing the risk of sustained kidney-function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in selected chronic kidney disease patients.[3]

When does Qtern lose exclusivity?

Qtern’s regulatory and patent exclusivity should be analyzed separately.

Exclusivity category Relevant date or status Commercial implication
FDA approval September 27, 2017 Established the U.S. product franchise
New chemical entity exclusivity Not applicable to Qtern as a fixed-dose combination of previously approved ingredients No five-year NCE period
Clinical-investigation exclusivity Potential three-year period associated with approval-supporting studies Protected the approved application from certain abbreviated applications during the applicable period
Combination-product patent U.S. Orange Book-listed patent protection has been associated with Qtern Can delay or complicate direct generic substitution
Dapagliflozin compound patents Core U.S. protection largely expired before or around the early 2020s, subject to patent-specific extensions and litigation Does not by itself determine Qtern entry
Saxagliptin compound patents Earlier than Qtern’s combination protection The active ingredient alone is not the principal long-term barrier
Pediatric exclusivity Must be verified against the applicable FDA listing and patent records Could add six months to qualifying protection

The key protection is the combination-product estate rather than the underlying active ingredients. A generic manufacturer may be able to challenge Qtern’s listed combination patent even after the individual dapagliflozin and saxagliptin patents have expired.

Public patent databases and FDA Orange Book records should be read together because patent expiration dates can differ based on patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and listing corrections.[4]

What patents protect Qtern?

Qtern’s patent protection is centered on fixed-dose combinations containing dapagliflozin and saxagliptin. U.S. patent records have associated the product with AstraZeneca entities and combination claims covering pharmaceutical compositions and methods of treating diabetes.

A commonly cited Qtern patent is U.S. Patent No. 9,669,097, with an expiration date reported in public patent databases in the early 2030s, subject to statutory adjustments and regulatory extensions. The patent’s relevance is greater than the earlier compound patents because it targets the co-formulated product rather than one active ingredient alone.[5]

Patent protection by layer

Patent layer Protected subject matter Strength for Qtern
Dapagliflozin compound patents SGLT2 inhibitor active ingredient Limited as a standalone barrier after expiration
Saxagliptin compound patents DPP-4 inhibitor active ingredient Limited as a standalone barrier after expiration
Fixed-dose combination patents Dapagliflozin plus saxagliptin compositions Core Qtern protection
Formulation patents Tablet composition, excipients, release and stability characteristics May complicate design-around strategies
Method-of-use patents Use of the combination in type 2 diabetes Relevant where listed and enforceable
Manufacturing patents Processes for producing active ingredients or dosage forms More important for supply-chain control than automatic product blocking

The practical strength of the estate depends on claim scope, prosecution history, validity challenges, and whether a generic applicant can formulate a non-infringing version. A patent directed narrowly to a specific ratio, excipient system, or formulation process may be easier to design around than a broad composition claim.

What is the Orange Book status of Qtern?

Qtern is an FDA-approved prescription drug whose patent listings must be assessed through the FDA’s Orange Book and related regulatory records. The Orange Book identifies patents that the NDA holder submits for the approved drug, but listing does not establish patent validity or infringement.[4]

A generic applicant seeking approval through an ANDA may make a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or will not be infringed. If the NDA holder brings suit within the statutory period, FDA approval of the ANDA can be subject to a 30-month stay, subject to court decisions and statutory exceptions.

No reliable public evidence establishes a commercially significant Qtern Paragraph IV launch challenge or a final judgment eliminating its principal listed combination patent. The absence of a public challenge does not prove that no certification has been filed, because litigation records, settlement terms, and regulatory correspondence may not fully disclose the commercial status of every filing.

Which companies are challenging Qtern?

The public record does not identify a major generic launch against Qtern comparable to the challenges directed at high-revenue products such as Farxiga, Januvia, or major oncology therapies.

Potential challengers include generic companies with diabetes portfolios and manufacturing capabilities in oral solid-dose products. The most likely entry route would be an ANDA supported by a Paragraph IV certification against the principal Qtern combination patent. A generic company could also pursue a different formulation or seek approval after listed patent expiry through Paragraph III certifications.

The economic incentive to challenge Qtern is lower than the incentive to challenge Farxiga. Qtern revenue is not separately reported as a major AstraZeneca product, while Farxiga generates multi-billion-dollar annual sales. Generic companies typically prioritize products with larger reimbursed markets, stronger pharmacy substitution potential, and less complex combination-product risk.

What formulation patents protect Qtern?

Qtern’s commercial product is a film-coated immediate-release tablet containing dapagliflozin and saxagliptin. Formulation protection may cover:

  • The co-presence of both active ingredients in one dosage form.
  • Specific active-ingredient ratios.
  • Excipients and tablet architecture.
  • Dissolution and stability characteristics.
  • Manufacturing conditions that preserve the performance of both compounds.

Formulation patents can create a secondary barrier after active-ingredient patents expire. Their value depends on whether the claims cover the clinically relevant product broadly or only a narrow manufacturing implementation.

A generic applicant may avoid infringement by using different excipients, compression conditions, coating systems, or particle characteristics, provided the resulting product satisfies FDA bioequivalence requirements. Qtern therefore has a more complex generic pathway than a conventional single-ingredient tablet, but it does not necessarily have an insurmountable barrier.

How has Qtern’s financial trajectory developed?

AstraZeneca has concentrated financial disclosure on the broader diabetes portfolio rather than Qtern as a standalone product. Farxiga is the company’s principal diabetes growth asset and has expanded through cardiovascular, renal, and heart-failure indications. Qtern has not been identified as a comparable growth driver in the company’s reported product portfolio.[1]

Financial trajectory

Period Market position Financial interpretation
2017-2019 New fixed-dose combination Initial uptake depended on patients already using or eligible for both components
2020-2021 Broader SGLT2 adoption Qtern competed with growing preference for SGLT2 monotherapy and other combinations
2022-2024 Farxiga expansion in heart failure and CKD Value shifted toward dapagliflozin’s outcome-based indications
Longer term Patent and generic pressure Combination-product protection may delay entry, but market growth is unlikely to match Farxiga

Qtern’s revenue exposure is likely modest relative to AstraZeneca’s total diabetes franchise. Because AstraZeneca does not consistently disclose Qtern sales as a separate material line item, analysts should avoid treating total Farxiga or total diabetes revenue as Qtern revenue.

A practical model should use Qtern as a declining or stable specialty product rather than a major revenue-growth asset. Key variables are:

  1. Net price after rebates and payer discounts.
  2. Whether payers prefer separate Farxiga and saxagliptin prescriptions.
  3. Generic availability of either component.
  4. Qtern’s formulary tier relative to Glyxambi and Trijardy XR.
  5. Physician preference for therapies with demonstrated cardiovascular and renal outcomes.
  6. Any future generic entry against the fixed-dose combination.

How does Qtern compare with Farxiga and Glyxambi?

Factor Qtern Farxiga Glyxambi
Components Dapagliflozin/saxagliptin Dapagliflozin Empagliflozin/linagliptin
Primary value proposition Dual oral glycemic control Glycemic, heart-failure and renal outcomes Dual oral glycemic control
Cardiovascular and renal label breadth Narrower Broader More limited relative to Farxiga
Manufacturer AstraZeneca AstraZeneca Boehringer Ingelheim/Eli Lilly
Main commercial risk Low growth and generic combination entry Future SGLT2 competition and patent loss Competition from Jardiance and fixed-dose combinations
Strategic role Franchise defense and adherence product Major growth and outcomes franchise Combination competitor

Qtern’s principal disadvantage is that its combination benefit is primarily glycemic, while Farxiga’s market expansion is tied to outcomes that extend beyond glucose lowering. Payers and clinicians have increasingly prioritized therapies with evidence in heart failure and chronic kidney disease.

What licensing deals affect Qtern?

AstraZeneca commercializes Qtern within its own dapagliflozin and saxagliptin diabetes franchise. No major separate Qtern-specific licensing transaction has been publicly identified as a central driver of the product’s commercial position.

The broader dapagliflozin franchise has been subject to collaboration and regional commercialization arrangements, particularly in relation to diabetes and cardiovascular products. Those arrangements should not be treated as Qtern-specific revenue-sharing agreements unless the contract expressly identifies Qtern.

What generic launch scenarios exist for Qtern?

Scenario 1: Delayed fixed-dose generic entry

A generic applicant challenges the combination patent, but litigation preserves market exclusivity until patent expiry or settlement. Qtern maintains branded pricing but faces declining utilization as physicians prescribe the individual components.

Scenario 2: At-risk launch

A generic manufacturer launches before final resolution after receiving a favorable litigation position. AstraZeneca could seek damages, an injunction, or other remedies. This scenario would create rapid price erosion if pharmacy substitution occurs.

Scenario 3: Separate-component substitution

Generic dapagliflozin and saxagliptin become available without a direct Qtern generic. Physicians and payers substitute the two individual products, reducing Qtern demand while avoiding direct infringement of a fixed-dose combination patent.

Scenario 4: Authorized generic or settlement entry

AstraZeneca could permit an authorized generic or settle with a challenger under terms that specify an entry date, license restrictions, or supply arrangements. No major public Qtern settlement has been established as the defining market event.

How strong is the Qtern patent estate?

Qtern’s patent estate is moderate rather than dominant.

Its strengths are:

  • A fixed-dose combination provides a distinct product claim relative to single-agent patents.
  • The product has two established active ingredients and a defined tablet formulation.
  • Generic developers must satisfy combination-product bioequivalence requirements.

Its weaknesses are:

  • The active ingredients are mature and widely understood.
  • The medical market increasingly favors broader outcome indications associated with dapagliflozin.
  • Generic manufacturers may design around narrow formulation claims.
  • Qtern’s relatively modest revenue reduces litigation incentives for both sides.
  • Separate generic components can erode demand without a direct Qtern copy.

Patent strength should therefore be measured by the ability to preserve Qtern’s net price and volume, not only by the nominal expiration date of a listed patent.

What patent litigation affects Qtern?

No major public litigation outcome has been identified as changing Qtern’s U.S. commercial status. The relevant litigation risk remains a potential Paragraph IV challenge to the listed fixed-dose combination patent.

A complete litigation review should distinguish:

  • ANDA patent litigation under the Hatch-Waxman Act.
  • Declaratory-judgment actions.
  • Patent-office post-grant proceedings.
  • Settlement agreements.
  • Foreign opposition and revocation proceedings.
  • Litigation involving Farxiga or Onglyza that does not directly affect Qtern.

Foreign patent outcomes may differ from U.S. outcomes because national courts assess validity and infringement independently. European, Canadian, Japanese, and other market positions should not be inferred from the U.S. Orange Book.

What geographic coverage does Qtern have?

Qtern has been marketed in multiple jurisdictions under AstraZeneca’s diabetes portfolio, but approval, reimbursement, patent coverage, and commercial availability vary by country. In some markets, the product may be known under a different brand or may face different regulatory treatment.

Geographic risk is highest where:

  • Combination patents have expired or were never granted.
  • Generic substitution is strong.
  • Payers favor separate low-cost components.
  • SGLT2 outcomes products receive preferential reimbursement.
  • Local manufacturing or compulsory-license rules affect supply.

The United States remains the most important patent and litigation jurisdiction because of Hatch-Waxman procedures, Orange Book listings, and the potential for Paragraph IV-driven market entry.

Key Takeaways

  • Qtern combines dapagliflozin and saxagliptin in a once-daily fixed-dose tablet.
  • AstraZeneca’s commercial strategy has shifted toward Farxiga’s heart-failure and chronic-kidney-disease indications.
  • Qtern is not a major separately reported revenue driver in AstraZeneca’s recent disclosures.
  • The core Qtern protection is the fixed-dose combination and formulation patent estate, not the older individual compound patents.
  • A commonly cited Qtern patent is U.S. Patent No. 9,669,097, with reported expiration in the early 2030s, subject to patent-term adjustments and regulatory extensions.
  • No major public Paragraph IV challenge or settlement has been established as the defining Qtern market event.
  • Generic erosion may occur through separate dapagliflozin and saxagliptin products even without a direct Qtern generic.
  • Qtern’s patent estate is moderate: it can delay direct combination entry but does not provide the commercial leverage of Farxiga’s broader outcomes franchise.

FAQs About Qtern Patents, Sales, and Generic Entry

Is Qtern the same as Farxiga?

No. Qtern contains dapagliflozin plus saxagliptin. Farxiga contains dapagliflozin alone and has broader FDA indications for heart failure and chronic kidney disease.

Does Qtern have new chemical entity exclusivity?

No. Qtern combines previously approved active ingredients and therefore does not receive a five-year NCE exclusivity period for a new active moiety.

Can generic companies substitute separate dapagliflozin and saxagliptin for Qtern?

Yes, subject to prescribing, payer, and substitution rules. Separate products may reduce Qtern demand even if no generic obtains approval for the Qtern fixed-dose tablet.

Does Qtern have an FDA pediatric extension?

The applicable FDA Orange Book and regulatory records must be reviewed for any pediatric exclusivity attached to a listed Qtern patent. A pediatric extension, if granted, can add six months to qualifying patent protection.

Is Qtern still commercially important to AstraZeneca?

Qtern remains part of AstraZeneca’s diabetes portfolio, but its strategic and financial importance is materially lower than Farxiga’s. AstraZeneca’s public reporting does not identify Qtern as a comparable standalone growth product.

References

  1. AstraZeneca. (2024). Annual report and Form 20-F 2023. AstraZeneca PLC.
  2. U.S. Food and Drug Administration. (2017). Qtern (dapagliflozin and saxagliptin) prescribing information.
  3. U.S. Food and Drug Administration. (2023). Farxiga (dapagliflozin) prescribing information.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  5. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,669,097: Dapagliflozin and saxagliptin pharmaceutical compositions.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.